GELLERT MICHAEL E 4
4 · Apellis Pharmaceuticals, Inc. · Filed Nov 13, 2017
Insider Transaction Report
Form 4
GELLERT MICHAEL E
10% Owner
Transactions
- Conversion
Common Stock
2017-11-13+798,068→ 943,989 total - Conversion
Series B Preferred Stock
2017-11-13−545,454→ 0 total→ Common Stock (255,721 underlying) - Conversion
Series C Preferred Stock
2017-11-13−556,830→ 0 total→ Common Stock (261,054 underlying) - Conversion
Series A Preferred Stock
2017-11-13−600,000→ 0 total→ Common Stock (281,293 underlying)
Footnotes (1)
- [F1]The Series A, Series B and Series C Preferred Stock converted into Common Stock on a 2.133-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.